Skip to content
The Nexus
DossierENTITY

Humira

Coverage of Humira in the Nexus archive.

Earliest in view: May 21 · 16:47 UTCMost recent: May 26 · 08:30 UTC
Co-mentioned in this coverage
AbbVieorganization2John Cornynperson1Richard Gonzalezperson1Senate Committee on Financeorganization1rheumatoid arthritistopic1inflammatory bowel diseasetopic1FDAorganization1Novo Nordiskorganization1Ozempictopic1Canadaplace1Eli Lillyorganization1United Statesplace1
Recent coverage
  • BUSINESSMay 26 · 08:30 UTCSTAT NEWS
    Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies

    Sen. John Cornyn questioned AbbVie CEO Richard Gonzalez during a 2019 congressional hearing about the company's 136 patents on Humira, a drug with the same active molecule used to treat multiple conditions. Gonzalez defended the patents as 'innovations,' extending patent protection beyond the original 2016 expiry. The exchange highlights concerns about pharmaceutical companies leveraging patent portfolios to maintain monopolies.

  • BUSINESSMay 21 · 16:47 UTCSEMAFOR
    Novo Nordisk lets Canadian patent expire

    Generic versions of Ozempic entered the Canadian market after Novo Nordisk allowed its patent to expire, possibly due to failing to pay a $250 filing fee. The move raises questions about whether this was strategic corporate planning or an expensive oversight, as it allows generics to compete while potentially avoiding statutory price caps on patented drugs.